- Randomized Controlled Trial of Anti-reflux Mucosectomy Versus Radiofrequency Energy Delivery for Proton Pump Inhibitor-refractory Gastroesophageal Reflux Disease
-
Wang Y, Lv M, Lin L, Jiang L
- KMID: 2544712
- J Neurogastroenterol Motil.
- 2023 Jul;29(3):306-313.
- doi: 10.5056/jnm21240
Background/Aims The efficacy and safety of anti-reflux mucosectomy (ARMS) or radiofrequency energy delivery in the treatment of gastroesophageal reflux disease (GERD) have been reported, but the difference between the 2 remains... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy
-
Ma Y, Zhu M, Zhang J, Lv M, Chen X, Liu Z
- KMID: 2547795
- Cancer Res Treat.
- 2023 Oct;55(4):1210-1221.
- doi: 10.4143/crt.2022.1633
Purpose Patients with human epidermal growth factor receptor 2 (HER2)–low advanced breast cancer can benefit from trastuzumab deruxtecan. Given the unclear prognostic characteristics of HER2-low breast cancer, we investigated the... -
- CITED
-
- Close
- SHARE
-
- Close
